Clinical Trial Update: Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TRO19622 as add-on therapy to riluzole in amyotrophic lateral sclerosis has been completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• TRO19622

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2019-02-15